CAGE Bio
CompanyUnited States
CAGE Bio develops one asset, in phase 3 (tofacitinib in rheumatoid arthritis). Mostly small molecule acting on JAK2, JAK1 and JAK3; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- Raised
- $25M
- 3
- Trials
- 6
- Signals
Pipeline
1Janus kinase (JAK) inhibitor that suppresses inflammatory cytokine signaling
Phase 3, Small molecule, JAK2, JAK1, rheumatoid arthritis, ankylosing spondylitis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials3
- Funding rounds and grants3
- People3
- Signals14
- Similar companies6